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set by the UK Renal Association standards’ committee in
2002.4 However, the UK Renal Association clinical guide-
lines committee has only recently reappraised the value of
pre- and post-dialysis blood pressure targets, and has
decided on the basis of the currently available data that no
guideline target should be recommended.5
One potential side effect of setting idealized post
hemodialysis blood pressure targets is that too high an
intradialytic ultrafiltration rate may lead to severe intradia-
lytic hypotension.6 In our study, symptomatic intradialytic
hypotension, requiring active intravenous fluid resuscita-
tion occurred in some 15% of all hemodialysis sessions.7
Intradialytic hypotension may potentially lead to myocardial
hypoperfusion, and cerebral watershed ischemia.8 The
incidence of symptomatic hypotension was associated with
greater absolute and percentage interdialytic weight gains.
Although Professor Shaldon and his colleagues suggested
that our study showed that those patients who took their
antihypertensive medication before hemodialysis suffered
greater intradialytic hypotension, this was not the case.
Interestingly whether patients took their antihypertensive
medications before dialysis or not had no impact on the
frequency of intradialytic hypotension.
We support the contention of Shaldon and colleagues
that sodium balance is important in the pathogenesis of
blood pressure control in chronic hemodialysis patients.
However, although convenient, the simple recording of
blood pressure before and following a hemodialysis session
would appear not to be an accurate reflection of
interdialytic blood pressure control.2 As such, the UK
Renal Association clinical guidelines subcommittee has
recently recognized that there is no good association
between patient survival and/or cardiovascular morbidity
and simple pre- and post-hemodialysis blood pressure
measurements, and as such has rescinded the previous
guideline targets.5 This does not imply that blood pressure
control is not important for hemodialysis patients, merely
that routine pre- and post-hemodialysis blood pressure
measurements are not sufficiently accurate assessments of
interdialytic blood pressure control, to be used to set
didactic targets.
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To the Editor: In a recent issue of Kidney International Eloot
et al.1 showed the independent effect of the factor time ‘t’ on
the adequacy of hemodialysis in a simple and smart way.
Even though the importance of t had already been stressed,2,3
its crucial role had always escaped the experimental
verification because of the difficulty in separating the role
of t from that of other variables. Furthermore, Eloot et al.1
were able to add new shadows to the many doubts and
inconsistencies about Kt/Vurea, as the standard marker for
dialysis adequacy, which had already come up in the
literature.4,5 On the contrary, the crucial role played by
t (and by diffusion), as shown by Eloot et al., leads to
a ‘unifying theory’ of the adequacy of dialysis, which puts in
agreement the kinetic theories of both small and middle
molecules, which are based on several and different
distribution volumes (single, double, and multiple pools).
The diffusive mechanism turns out to be more efficient
simply because of an increase in t: consequently, it turns out
to be more effective clinically because it increases the total
solute removals, the total cleared volumes (Kt), and the
dialyzer extraction ratios of urea, creatinine, phosphorus,
and b2-microglobulin in a statistically significant way.
1 Kt/
Vurea did not change in a statistically significant way.
1
The authors did not explain why; however, we can infer
from the data that, due to the fact that Kt increased, the only
way to keep the ratio Kt/V constant is through an increase in
V. In other words, it means that, when we prescribe a dialysis
t of 4 h, Kt will have a lower value and, consequently, V will
have a value (V0), which does not correspond to the real
distribution V of urea. This effect is amplified by the
higher and higher extraction velocities of the solute which
occur in a standard dialysis treatment, in which dialysate and
blood flows are kept higher and higher: in this situation a sort
of relativity of V with respect to the solute extraction
velocities is more evident. On the contrary, when we
prescribe a dialysis t of 6 h, Kt will have a higher value and,
consequently, V will have a value which is V0þ (V1V0);
and, increasing dialysis t to 8 h, V will have a value which is
V0þ (V1V0)þ (V2V1). In other words, with longer
dialyses, the deeper compartments of the patient’s body are
cleared in such a way that the distribution V of urea tends to
behave as a unique single pool. The same type of reasoning
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applied to Kt/Vurea may be applied to Kt/V of other uremic
retention solutes. In conclusion, it is time to work out a new
theory of the adequacy of dialysis: the paper by Eloot et al.1
has the merit of providing experimental data which allow to
separate the effect of t from that of other variables.
Furthermore, it has the merit of simplifying the conceptual
scenario of adequacy of dialysis and of drawing the focus on
the diffusive mechanisms as the key modality of the removal
of uremic retention solutes.1
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To the Editor: We read with interest the article by Lopez
et al.1 They compared the effects of AMG 641 with calcitriol
(CT) or paricalcitol (PC) alone, and the combination of the
calcimimetic with either CT or PC. We have really found the
paper interesting, but would like to raise some points of
discussion.
Not surprisingly, CT administration induced extraskeletal
calcifications (EC), reduced survival, increased aortic calcium
(Ca) and phosphorous deposition, and enhanced mineral
content in the lung and stomach. Contrary to our
expectations and recent literature data, also PC administra-
tion did not prevent EC and aortic Ca and phosphorous
deposition. Unfortunately, the authors did not comment in
their paper to at least other two new published articles with
opposite results on this topic,2,3 and we believe that the
debate needs to be opened.
It is diffusely agreed that dialysis patients develop
extensive EC, which causes increased arterial stiffness and
high morbidity and mortality because of cardiovascular
events. A variety of risk factors are associated with EC in
dialysis patients (time on dialysis, uremic toxins, history of
diabetes, inflammation), but abnormalities in bone mineral
metabolism may play a critical role.4 In this direction, both
vitamin D receptor activators and calcimimetics represent
new tools in the treatment of secondary hyperparathyroidism
and EC.
In experimental animal models, the limited hypercalcemic
effect of PC results from a lower affinity for vitamin D
receptor in intestine and bone. In addition, PC causes a
selective vitamin D activation and a reduction in intestinal
Ca absorption.5 Recently, an in vitro study demonstrated that
CT increased calcification of vascular smooth muscle cells
cultured in calcification media, but this effect was not present
when cells were incubated with PC.2 Moreover, in an in vivo
study Mizobuchi et al.3 showed that both CT and
doxercalciferol significantly increased the serum Ca and
phosphorous product and aortic Ca content in uremic rats.
In contrast, PC had no effect on EC.
Finally, recent prospective studies demonstrated that
hemodialysis patients receiving low doses of PC intrave-
nously have a reduced mortality risk compared to untreated
patients6 and that PC has a survival benefit over CT.7
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We thank Dr Cozzolino and Dr Brancaccio for their interest
in our recently published article in which we investigated the
effect of calcitriol, paricalcitol, and the research calcimimetic
AMG 641, alone or in combination, on the development of
vascular and other soft tissue calcifications in a rat model of
uremia-associated secondary hyperparathyroidism (HPT).
After completing this study we concluded that the calcimi-
metic AMG 641 reduces parathyroid hormone (PTH)
without inducing extraskeletal calcifications under condi-
tions in which the vitamin D derivatives did.1
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